La chaîne d'options affiche les données clés des options sur actions de Janus Henderson Group à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Janus Henderson Group..

Janus Henderson Group (NYSE:JHG) Stock, Chaîne d'Options

Janus Henderson Group

Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.

Janus Henderson Group plc Ordinary Shares

Janus Henderson Group PLC

UBS analyst Joshua Spector maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and lowers the price target from $74 to $73.

News

Price Target

Analyst Ratings

CTVA

UBS Maintains Buy on Corteva, Lowers Price Target to $73

On Thursday, Truist initiated coverage on BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
BioNTech is transitioning from a COVID-focused narrative to a story centered on oncology drug development <a target="_blank" href="https://www.benzinga.com/24/12/42370209/why-is-biontech-stock-trading-higher-on-friday" rel="noreferrer noopener">and upcoming catalysts.</a>
The analyst, Asthika Goonewardene, writes that BNT327 is at the forefront, a promising drug in an innovative class that could challenge and potentially surpass the PD-1 category, which generated over $42 billion in 2023.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41866389/biontech-earns-upgrade-from-goldman-sachs-as-investment-thesis-shifts-toward-cancer-potential" rel="noreferrer noopener">BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential</a>
While Summit Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) ivonescimab may have a head start in certain areas, BioNTech&#8217;s stronger financial position and pipeline of complementary products give it a strategic edge. With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds.
In November, BioNTech agreed to acquire&nbsp;Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41949384/biontech-boosts-oncology-strategy-with-800-million-china-based-biotheus-acquisition" rel="noreferrer noopener">oncological or inflammatory diseases</a>.
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
Truist initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/BNTX/analyst-ratings" rel="noreferrer noopener">price target of $172</a>.
BioNTech&#8217;s oncology pipeline was previously seen as limited in value outside BNT316. However, with BNT327 gaining traction and new data expected in 2025 to clarify the potential of other pipeline assets, there is room for greater investor appreciation of the company&#8217;s oncology portfolio, Truist analyst adds.
Goonewardene also writes that <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">COVID-19 remains a significant factor</a> in BioNTech&#8217;s stock performance and that COVID-related developments will continue to influence BioNTech&#8217;s stock.
The analyst highlights that BNT327 could be the first drug approved in the U.S. and Europe for key conditions like triple-negative breast cancer and small cell lung cancer, potentially generating around $2 billion at peak sales.
For non-small cell lung cancer, Truist expects BNT327 to follow shortly, contributing over $4 billion in revenue.
Price Action: BNTX stock is up 0.55% at $122.82 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42918973/wayfair-waves-goodbye-to-germany-heres-why" target="_blank" rel="noreferrer noopener">Wayfair Waves Goodbye To Germany &#8211; Here&#8217;s Why</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Biotech

Equities

Large Cap

Initiation

Trading Ideas

General

BNTX

SMMT

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

WIIM

SPGI

S&P Global shares are trading lower after Wells Fargo cut its price target on the stock from $620 to $617.

UBS analyst Joshua Spector maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Neutral and lowers the price target from $235 to $207.

UBS Maintains Neutral on Avery Dennison, Lowers Price Target to $207

UBS analyst Curt Woodworth maintains Ardagh Metal Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>) with a Neutral and lowers the price target from $4.25 to $2.75.

AMBP

UBS Maintains Neutral on Ardagh Metal Packaging, Lowers Price Target to $2.75

STNG

TALO

TRGP

VTLE

Shares of oil, gas and tanker companies are trading higher following reports suggesting the US is preparing sanctions against Russian oil and gas.

UBS analyst Joshua Spector maintains Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Neutral and lowers the price target from $75 to $72.

BERY

UBS Maintains Neutral on Berry Global Gr, Lowers Price Target to $72

Macro Economic Events

Economics

Oil is trading higher following reports suggesting the US is preparing sanctions against Russian oil and gas.

UBS analyst Curt Woodworth maintains Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Buy and lowers the price target from $113 to $108.

UBS Maintains Buy on Crown Holdings, Lowers Price Target to $108

UBS analyst Joshua Spector maintains Sealed Air (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) with a Neutral and lowers the price target from $39 to $37.

UBS Maintains Neutral on Sealed Air, Lowers Price Target to $37

Affirm Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NYSE">AFRM</a>) short percent of float has fallen 8.86% since its last report. The company recently reported that it has 15.02 million shares sold short, which is 5.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Affirm Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736538321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Affirm Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Affirm Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Affirm Holdings's peer group average for short interest as a percentage of float is 5.01%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

AFRM

Peering Into Affirm Holdings's Recent Short Interest

Philip Morris Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) short percent of float has risen 23.73% since its last report. The company recently reported that it has 11.39 million shares sold short, which is 0.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Philip Morris Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736538315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Philip Morris Intl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Philip Morris Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Philip Morris Intl's peer group average for short interest as a percentage of float is 1.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(PM) - Analyzing Philip Morris Intl's Short Interest

Colgate-Palmolive's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) short percent of float has risen 4.59% since its last report. The company recently reported that it has 9.29 million shares sold short, which is 1.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Colgate-Palmolive Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736538310_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Colgate-Palmolive has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Colgate-Palmolive's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Colgate-Palmolive's peer group average for short interest as a percentage of float is 6.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Colgate-Palmolive's Recent Short Interest

Susquehanna analyst Biju Perincheril downgrades Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) from Positive to Neutral and lowers the price target from $9 to $7.

Downgrades

ARRY

Susquehanna Downgrades Array Technologies to Neutral, Lowers Price Target to $7

AENT

ALUR

BKNG

CVNA

New Oriental Education & Technology Group

GROV

MBLY

MMYT

RIME

SPGC

WRBY

YUMC

ZSPC

Shares of companies within the broader consumer discretionary sector are trading lower amid overall market weakness due to a rise in yields.

FFIE

LVWR

MULN

Shares of auto companies are trading lower amid overall market weakness due to a rise in yields.

Susquehanna analyst Biju Perincheril downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Positive to Neutral and lowers the price target from $14 to $4.5.

NOVA

Susquehanna Downgrades Sunnova Energy Intl to Neutral, Lowers Price Target to $4.5

On Wednesday,&nbsp;Vir Biotechnology, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42881652/vir-biotechnology-stock-jumps-after-prostate-cancer-trial-data" rel="noreferrer noopener">prostate cancer (mCRPC)</a>.
Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome, maximum tolerated dose not yet reached as dose escalation continues, and early clinical response signals observed in heavily pretreated participants.
On Thursday, Morgan Stanley upgraded Vir Biotechnology, noting that &#8220;initial data provide early platform de-risking and see potential for activity to improve as dose escalation continues.&#8221;
Early efficacy data indicate that 50% (10/20) of participants receiving VIR-5818 doses ≥400 µg/kg experienced dose-dependent tumor shrinkage across multiple HER2-positive tumor types.
Analyst Michael E Ulz, citing management, writes that the response rate of ~33% is adequate to accelerate development.
The analyst upgrades Vir Biotechnology from Equal-weight to Overweight with a price target of $20, <a target="_blank" href="https://www.benzinga.com/quote/VIR/analyst-ratings" rel="noreferrer noopener">up from $10</a>.
The Morgan Stanley analyst is optimistic about the early results, showing promising activity and manageable safety in both programs. They are awaiting data from higher doses to confirm safety and see stronger effectiveness.
Analyst Michael E Ulz writes that encouraging early results de-risks the TCE platform.
The model now includes VIR-5500 revenue projections for prostate cancer and slightly lower operating expenses based on revised cash guidance. However, the analyst has removed Hepatitis B revenues.
Price Action: VIR stock is up 0.24% at $12.51 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42920173/jack-ma-highlights-ais-future-impact-amid-biden-governments-sanction-speculations-on-china" target="_blank" rel="noreferrer noopener">Jack Ma Highlights AI&#8217;s Future Impact Amid Biden Government&#8217;s Sanction Speculations on China</a></li>
</ul>
Photo via Shutterstock.

Upgrades

Health Care

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Financial giants have made a conspicuous bearish move on Kinder Morgan. Our analysis of options history for Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) revealed 9 unusual trades.
Delving into the details, we found 22% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $100,604, and 6 were calls, valued at $627,490.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Kinder Morgan during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Kinder Morgan stands at 11543.75, with a total volume reaching 4,377.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Kinder Morgan, situated within the strike price corridor from $20.0 to $30.0, throughout the last 30 days.
<h3>Kinder Morgan Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736537431_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KMI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.35</td>
<td>$8.3</td>
<td>$8.35</td>
<td>$20.00</td>
<td>$207.0K</td>
<td>42.5K</td>
<td align="right">791</td>
</tr>
<tr>
<td>KMI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.4</td>
<td>$8.3</td>
<td>$8.33</td>
<td>$20.00</td>
<td>$124.9K</td>
<td>42.5K</td>
<td align="right">486</td>
</tr>
<tr>
<td>KMI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.35</td>
<td>$8.3</td>
<td>$8.33</td>
<td>$20.00</td>
<td>$87.4K</td>
<td>42.5K</td>
<td align="right">896</td>
</tr>
<tr>
<td>KMI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.35</td>
<td>$8.3</td>
<td>$8.32</td>
<td>$20.00</td>
<td>$83.2K</td>
<td>42.5K</td>
<td align="right">186</td>
</tr>
<tr>
<td>KMI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.35</td>
<td>$8.3</td>
<td>$8.32</td>
<td>$20.00</td>
<td>$62.4K</td>
<td>42.5K</td>
<td align="right">336</td>
</tr>
</tbody>
</table>

<h3>About Kinder Morgan</h3>
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 82,000 miles in pipelines and 139 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Following our analysis of the options activities associated with Kinder Morgan, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Kinder Morgan</h3>
<ul>
<li>Trading volume stands at 6,000,791, with KMI's price down by -0.02%, positioned at $28.29.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 11 days.</li>
</ul>
<h3>Expert Opinions on Kinder Morgan</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $27.666666666666668.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Kinder Morgan with a target price of $30. 
&#x2A; An analyst from Scotiabank downgraded its action to Sector Perform with a price target of $26. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Kinder Morgan with a target price of $27. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Kinder Morgan with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Smart Money Is Betting Big In KMI Options

Deep-pocketed investors have adopted a bullish approach towards GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for GE Aero. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 52% leaning bullish and 29% bearish. Among these notable options, 11 are puts, totaling $686,431, and 6 are calls, amounting to $315,775.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $150.0 to $200.0 for GE Aero during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of GE Aero stands at 1146.18, with a total volume reaching 2,745.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in GE Aero, situated within the strike price corridor from $150.0 to $200.0, throughout the last 30 days.
<h3>GE Aero 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736537426_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$26.0</td>
<td>$25.95</td>
<td>$25.95</td>
<td>$150.00</td>
<td>$155.9K</td>
<td align="right">205</td>
<td align="right">0</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$11.15</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$175.00</td>
<td>$84.0K</td>
<td align="right">969</td>
<td align="right">435</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.6</td>
<td>$10.95</td>
<td>$11.19</td>
<td>$175.00</td>
<td>$77.1K</td>
<td align="right">969</td>
<td align="right">219</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.2</td>
<td>$11.0</td>
<td>$11.14</td>
<td>$175.00</td>
<td>$75.7K</td>
<td align="right">969</td>
<td align="right">154</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.2</td>
<td>$11.15</td>
<td>$11.15</td>
<td>$175.00</td>
<td>$74.7K</td>
<td align="right">969</td>
<td align="right">86</td>
</tr>
</tbody>
</table>

<h3>About GE Aero</h3>
GE Aerospace is the global leader in designing, manufacturing, and servicing large aircraft engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 70,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000. GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.
Following our analysis of the options activities associated with GE Aero, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of GE Aero</h3>
<ul>
<li>With a trading volume of 2,884,285, the price of GE is down by -0.13%, reaching $172.66.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 13 days from now.</li>
</ul>
<h3>What Analysts Are Saying About GE Aero</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $228.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Deutsche Bank continues to hold a Buy rating for GE Aero, targeting a price of $228. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for GE Aero, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on GE Aero: Analyzing the Surge in Options Activity

Janus Henderson Mortgage-Backed Securities ETF Q3 2024 Commentary

Janus Henderson Small Cap Value Fund Q3 2024 Commentary

Janus Henderson Overseas ADR Managed Account Q3 2024 Commentary

Janus Henderson Small-Mid Cap Value Fund Q3 2024 Commentary

Wells Fargo analyst Michael Brown maintained a Hold rating on Janus Henderson Group (JHG – Research Report) today and set a price target of $45.00....

Wells Fargo Sticks to Their Hold Rating for Janus Henderson Group (JHG)

Morgan Stanley analyst Michael Cyprys raised the firm's price target on Janus Henderson (JHG) to $48 from $46 and keeps an Equal Weight rating on t...

Janus Henderson price target raised to $48 from $46 at Morgan Stanley

Five reasons why UBS is overweight the UK

Janus Henderson Group (JHG – Research Report) received a Hold rating and price target from Goldman Sachs analyst Alexander Blostein today. The comp...

Goldman Sachs upgrades Janus Henderson Group (JHG) to a Hold

Goldman Sachs analyst Alexander Blostein upgraded Janus Henderson (JHG) to Neutral from Sell with a price target of $45, up from $42, implying 4% u...

Janus Henderson upgraded to Neutral from Sell at Goldman Sachs

JPMorgan lowered the firm's price target on Janus Henderson (JHG) to $44 from $45 and keeps a Neutral rating on the shares. The firm made several c...

Janus Henderson price target lowered to $44 from $45 at JPMorgan

AAGIY

AAIGF

ABCB

ASML

BAESF

BAESY

BBWI

BNPQF

BNPQY

BYDGF

CHRD

CNTA

COLB

DCNSF

DINO

DLICY

DTEGF

DTEGY

FBIN

GRRR

HEINY

HINKF

HLIO

ICAGY

IEUR

IMBBY

INTC

JAAA

JBBB

JMBS

JSMD

JSML

LAMR

MCHP

MTUS

PIPR

RBGLY

RBSPF

RKLIF

ROIV

SMGZY

SMSEY

SMSOF

TECK

TSCDY

UNLYF

VNLA

VRNA

WFRD

WTFC

ZLAB

Press Releases

Celebrating Three Decades of Impact: The Janus Henderson Foundation Marks its 30th Anniversary with over US$48 Million Donated to Grassroots Charities

Janus Henderson to Partner with Anemoy and Centrifuge on Its First Tokenized Fund

Janus Henderson Offers Money Market Fund to Support the American Cancer Society's Efforts in Advocacy, Research & Patient Support

Janus Henderson to Report Third Quarter 2024 Results

Almost Half of Americans Have No Investments and a Third Cite a Lack of Investment Understanding as the Main Reason Finds New Research from Janus Henderson

Comments

Janus Henderson Group

Janus Henderson Group (JHG) Options

Janus Henderson Group (NYSE:JHG) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL